AstraZeneca aims to redefine cancer care with the ambition to eliminate cancer as a cause of death  

AstraZeneca has partnered with Susan G. Komen supporting various patient education, navigation, health equity and research efforts to ensure that people with breast cancer can receive optimal care and support throughout their lifetime. Through these collaborations, AstraZeneca is committed to supporting the breast cancer community at every step of the journey, from diagnosis to treatment and beyond by bringing new innovative medicines to patients while partnering on programs that connect patients to essential resources for their care. 

AstraZeneca is leading the charge to redefine how breast cancer is classified and treated to deliver even more effective treatments for patients across all subtypes and stages. With a robust clinical trial program and an industry-leading portfolio, AstraZeneca’s ambition is to help contribute to the elimination of breast cancer as a cause of death. 

About AstraZeneca: 
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.